Crinetics Pharmaceuticals (NASDAQ:CRNX) reported quarterly losses of $(1.14) per share which beat the analyst consensus estimate of $(1.24) by 8.06 percent. This is a 7.32 percent increase over losses of $(1.23) per share from the same period last year. The company reported quarterly sales of $25.118 million which beat the analyst consensus estimate of $14.840 million by 69.26 percent. This is a 2.34K percent increase over sales of $1.031 million the same period last year.